Short answer
Voyager Therapeutics, Inc. (VYGR) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $13M (down 45.7% year over year) with net income of −$28M.
Q3 2025 key financials · XBRL
- Revenue
- $13M
- −45.7% YoY · +157.0% QoQ
- Net income
- −$28M
- −208.4% YoY · +16.4% QoQ
- Operating margin
- -228.9%
- EPS (diluted)
- −$0.47
- −193.7% YoY · +17.5% QoQ
Source: XBRL data from the Voyager Therapeutics, Inc. (VYGR) Q3 2025 10-Q on SEC EDGAR. USD.
Voyager Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net loss $92.3M for nine months ended September 30, 2025
- Accumulated deficit $418.5M as of September 30, 2025
- Expenses expected to increase substantially from VY7523 trials and platform investments
- VY7523 initial data expected second half 2026; VY1706 IND and trial anticipated in 2026
Risk Factors
- No material risk-factor changes disclosed from December 31, 2024 Form 10-K
- Carried-forward business risk: unidentified or currently less-significant risks could impair operations
- Near-term performance risk: previously disclosed risks could adversely affect future growth prospects
- Compliance disclosure: director Nancy Vitale adopted a Rule 10b5-1 plan covering up to 137,000 shares through September 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Voyager Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.